$80.00
▲ +2.7% Today
as of Sep 4, 16:50 ET
Last 30 days
Recent Press Releases & News
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
Kiniksa's Sales Are Expected To Decline — Why That's All According To Plan
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3
Overview
52-week range
$35
$83
94% of range
Avg surprise (last 2)
+238.9%
Avg reaction (last 1)
+20.5%
100% positive
Latest IV / EM
47%
EM ±7.3% · $80 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $0.27 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $0.23 | — | — | — | — | financials |
| Tue Jul 29, 2025 | Jun/2025 | $0.23 | $0.18 | +27.8% | — | — | earnings |
| Tue Apr 29, 2025 | Mar/2025 | $0.11 | $0.02 | +450.0% | — | +20.5% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.18 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.06 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.25 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.20 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.21 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.18 | — | — | — | — | financials |
| Fri Sep 30, 2022 | Sep 2022 | $3.18 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $214M | — | $181M | $157M | $138M | — | $112M | $109M |
| Cost of revenue | $21M | — | $20M | $19M | $18M | — | $20M | $12M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $29M | — | $24M | $20M | $13M | — | $-10M | $-117,000 |
| Net income | $23M | — | $18M | $18M | $9M | — | $-13M | $-4M |
| EPS (diluted) | $0.27 | — | $0.23 | $0.23 | $0.11 | — | $-0.18 | $-0.06 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $190M | $166M | $175M | $192M | $157M | $184M | $97M | $99M |
| Inventory | $73M | $55M | $41M | $48M | $22M | $26M | $29M | $35M |
| Total current assets | $594M | $527M | $476M | $420M | $356M | $332M | $311M | $301M |
| Total assets | $825M | $764M | $712M | $661M | $599M | $581M | $555M | $542M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $220M | $196M | $177M | $166M | $142M | $142M | $118M | $107M |
| Total equity | $606M | $568M | $535M | $495M | $457M | $438M | $437M | $435M |